TumorDiagnostik & Therapie, Table of Contents TumorDiagnostik & Therapie 2011; 32(06): 333-337DOI: 10.1055/s-0031-1281830 Thieme Onkologie aktuell © Georg Thieme Verlag KG Stuttgart · New York ·Epigenetische Modifikationen in malignen ZellenRelevanz für die Therapie von myelodysplastischem Syndrom und akuter myeloischer LeukämieEpigenetic changes in malignant cellsRelevance for the treatment of myelodysplastic syndrome and acute myeloic leukemia B. Hackanson , M. LübbertRecommend Article Abstract Buy Article Zusammenfassung Abstract Schlüsselwörter SchlüsselwörterEpigenetik - DNA-Methylierung - Histone Key words Key wordsepigenetics - DNA methylisation - histones Full Text References Literatur 1 Almstedt M, Blagitko-Dorfs N, Duque-Afonso J et al. The DNA demethylating agent 5-aza-2´- deoxycytidine induces expression of NY-ESO-1 and other cancer/testis antigens in myeloid leukemia cells. Leuk Res 2010; 34: 899-905 2 Borthakur G, Ahdab SE, Ravandi F et al. Activity of decitabine in patients with myelodysplastic syndrome previously treated with azacitidine. Leuk Lymphoma 2008; 49: 690-695 3 Cashen AF, Schiller GJ, O'Donnell MR et al. Multicenter, phase II study of decitabine for the first-line treatment of older patients with acute myeloid leukemia. Clin Oncol 2010; 28: 556-561 4 Fenaux P, Mufti GJ, Hellström-Lindberg E et al. Azacitidine prolongs overall survival compared with conventional care regimens in elderly patients with low bone marrow blast count acute myeloid leukemia. J Clin Oncol 2010; 28: 562-569 5 Fenaux P, Mufti GJ, Hellström-Lindberg E et al. Efficacy of azacitidine compared with that of conventional care regimens in the treatment of higher-risk myelodysplastic syndromes: a randomised, open-label, phase III study. Lancet Oncol 2009; 10: 223-232 6 Field T, Perkins J, Huang Y et al. 5-Azacitidine for myelodysplasia before allogeneic hematopoietic cell transplantation. Bone Marrow Transplant 2010; 45: 255-260 7 Flotho C, Claus R, Batz C et al. The DNA methyltransferase inhibitors azacitidine, Decitabine and zebularine exert differential effects on cancer gene expression in acute myeloid leukemia cells. Leukemia 2009; 23: 1019-1028 8 Garcia-Manero G, Yang H, Bueso-Ramos C et al. Phase 1 study of the histone deacetylase inhibitor vorinostat (suberoylanilide hydroxamic acid [SAHA]) in patients with advanced leukemias and myelodysplastic syndromes. Blood 2008; 111: 1060-1066 9 Goodyear O, Agathanggelou A, Novitzky-Basso I et al. Induction of a CD8+ T-cell response to the MAGE cancer testis antigen by combined treatment with azacitidine and sodium valproate in patients with acute myeloid leukemia and myelodysplasia. Blood 2010; 116: 1908-1918 10 Hackanson B, Guo Y, Lübbert M. The silence of the genes: epigenetic disturbances in haematopoietic malignancies. Expert Opin Ther Targets 2005; 9: 45-61 11 Issa JPJ, Kantarjian HM. Targeting DNA methylation. Clin Cancer Res 2009; 15: 3938-3946 12 Kantarjian H, Issa JP, Rosenfeld CS et al. Decitabine improves patient outcomes in myelodysplastic syndromes: results of a phase III randomized study. Cancer 2006; 106: 1794-1803 13 Kornblith AB, Herndon 2nd JE, Silverman LR et al. Impact of azacytidine on the quality of life of patients with myelodysplastic syndrome treated in a randomized phase III trial: a Cancer and Leukemia Group B study. J Clin Oncol 2002; 20: 2441-2452 14 Kuendgen A, Schmid M, Schlenk R et al. The histone deacetylase (HDAC) inhibitor valproic acid as monotherapy or in combination with all-trans retinoic acid in patients with acute myeloid leukemia. Cancer 2006; 106: 112-119 15 Ley TJ, Ding L, Walter MJ et al. DNMT3A mutations in acute myeloid leukemia. N Engl J Med 2010; 363: 2424-2433 16 Lübbert M, Bertz H, Rüter B et al. Non-intensive treatment with low-dose 5-aza-2´- deoxycytidine (DAC) prior to allogeneic blood SCT of older MDS/AML patients. Bone Marrow Transplant 2009; 44: 585-588 17 Lübbert M, Suciu S, Baila L et al. Low-dose decitabine vs. best supportive care in elderly patients with intermediate- or high-risk MDS ineligible for intensive chemotherapy: final results of the randomized phase III study of the EORTC Leukemia Group and the German MDS Study Group. J Clin Oncol 2011; in press 18 Marcucci G, Haferlach T, Döhner H. Molecular genetics of adult acute myeloid leukemia: prognostic and therapeutic implications. J Clin Oncol 2011; 29: 475-486 19 Möller I, Blum S, Gattermann N et al. Repeated responses of an elderly patient with high-risk myelodysplastic syndrome to sequential therapy with tipifarnib, 5-azacitidine, and decitabine. Ann Hematol 2009; 88: 1141-1144 20 Silverman LR, Demakos EP, Peterson BL et al. Randomized controlled trial of azacitidine in patients with the myelodysplastic syndrome: a study of the cancer and leukemia group B. J Clin Oncol 2002; 20: 2429-2440 21 Wagner J, Hackanson B, Lübbert M et al. Histone deacetylase (HDAC) inhibitors in recent clinical trials for cancer therapy. Clin Epigenet 2010; 1: 117-136
